Figure 3

Recurrence-free survival in ER-positive patients with different genotypes of CYP3A5 and tamoxifen randomisation. The solid line represents patients homozygous or heterozygous for the CYP3A5*1 allele, and the dotted line represents patients homozygous for the CYP3A5*3 allele. (a) CYP3A5 and 2 years of tamoxifen therapy; (b) CYP3A5 and 5 years of tamoxifen therapy.